New selective carbonic anhydrase IX inhibitors: Synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides

authors

• Rogez Florent Tiphaine
• Meignan Samuel
• Foulon Catherine
• Six Perrine
• Gros Abigaelle
• Bal-Mahieu Christine
• Supuran Claudiu T.
• Scozzafava Andrea
• Frederick Raphael
• Masereel Bernard
• Depreux Patrick
• Lansiaux Amélie
• Goossens Jean-François
• Gluszok Sébastien
• Goossens Laurence

keywords

• Hypoxia
• Breast cancer
• Pyrazole
• Carbonic anhydrase
• Doxorubicin
• Aryl sulfonamide inhibitors

abstract

Carbonic anhydrase (CA) IX expression is increased upon hypoxia and has been proposed as a therapeutic target since it has been associated with poor prognosis, tumor progression and pH regulation. We report the synthesis and the pharmacological evaluation of a new class of human carbonic anhydrase (hCA) inhibitors, 4-(5-aryl-2-hydroxymethyl-pyrazol-1-yl)-benzenesulfonamides. A molecular modeling study was conducted in order to simulate the binding mode of this new family of enzyme inhibitors within the active site of hCA IX. Pharmacological studies revealed high hCA IX inhibitory potency in the parameters nanomolar range. This study showed that the position of sulfonamide group in meta of the 1-phenylpyrazole increase a selectivity hCA IX versus hCA II of our compounds. An in vitro antiproliferative screening has been performed on the breast cancer MDA-MB-231 cell using doxorubicin as cytotoxic agent and in presence of selected CA IX inhibitor. The results shown that the cytotoxic efficiency of doxorubicin in an hypoxic environment, expressed in IC50 value, is restored at 20% level with 1 μM CA IX inhibitor.

more information